Login / Signup

First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.

Lan ShenTan QiangZiming LiDing DingYongfeng YuShun Lu
Published in: Cancer medicine (2020)
Our results suggested that first-line crizotinib had higher ORR and longer PFS than platinum-pemetrexed chemotherapy in patients with advanced ROS1+NSCLC, but the differences were not observed for OS.
Keyphrases
  • advanced non small cell lung cancer
  • small cell lung cancer
  • epidermal growth factor receptor
  • locally advanced
  • cell death
  • dna damage
  • reactive oxygen species
  • squamous cell carcinoma
  • tyrosine kinase
  • rectal cancer